Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer.
Loriot Y, Balar AV, Petrylak DP, Kalebasty AR, Grivas P, Fléchon A, Jain RK, Swami U, Bupathi M, Barthélémy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zavodovskaya M, Elboudwarej E, Diehl L, Jürgensmeier JM, Tagawa ST. Loriot Y, et al. Among authors: beuzeboc p. Clin Cancer Res. 2024 Aug 1;30(15):3179-3188. doi: 10.1158/1078-0432.CCR-23-3924. Clin Cancer Res. 2024. PMID: 39086310 Clinical Trial.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators. Smith MR, et al. N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8. N Engl J Med. 2018. PMID: 29420164 Free article. Clinical Trial.
Drug management of prostate cancer: prevalence and consequences of renal insufficiency.
Launay-Vacher V, Ayllon J, Janus N, Spano JP, Ray-Coquard I, Gligorov J, Pourrat X, Morere JF, Beuzeboc P, Deray G, Oudard S; Renal Insufficiency and Anticancer Medications (IRMA) Study Group. Launay-Vacher V, et al. Among authors: beuzeboc p. Clin Genitourin Cancer. 2009 Oct;7(3):E83-9. doi: 10.3816/CGC.2009.n.029. Clin Genitourin Cancer. 2009. PMID: 19815487
Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, Duquesne I, Lavaud P, Nicotra C, Ngocamus M, Lacroix L, Tselikas L, Crehange G, Friboulet L, Castel-Ajgal Z, Neuzillet Y, Borcoman E, Beuzeboc P, Marret G, Gutman T, Wong J, Radvanyi F, Dureau S, Scoazec JY, Servant N, Allory Y, Besse B, Andre F, Le Tourneau C, Massard C, Bieche I. Loriot Y, et al. Among authors: beuzeboc p. Nat Commun. 2024 Oct 30;15(1):9370. doi: 10.1038/s41467-024-53775-4. Nat Commun. 2024. PMID: 39478018 Free PMC article. No abstract available.
The genomic and transcriptomic landscape of metastastic urothelial cancer.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, Duquesne I, Lavaud P, Nicotra C, Ngocamus M, Lacroix L, Tselikas L, Crehange G, Friboulet L, Castel-Ajgal Z, Neuzillet Y, Borcoman E, Beuzeboc P, Marret G, Gutman T, Wong J, Radvanyi F, Dureau S, Scoazec JY, Servant N, Allory Y, Besse B, Andre F, Le Tourneau C, Massard C, Bieche I. Loriot Y, et al. Among authors: beuzeboc p. Nat Commun. 2024 Oct 4;15(1):8603. doi: 10.1038/s41467-024-52915-0. Nat Commun. 2024. PMID: 39366934 Free PMC article.
Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.
Chamorey E, Pujalte-Martin M, Ferrero JM, Mahammedi H, Gravis G, Roubaud G, Beuzeboc P, Largillier R, Borchiellini D, Linassier C, Bouges H, Etienne-Grimaldi MC, Schiappa R, Gal J, Milano G. Chamorey E, et al. Among authors: beuzeboc p. Int J Mol Sci. 2024 May 31;25(11):6058. doi: 10.3390/ijms25116058. Int J Mol Sci. 2024. PMID: 38892246 Free PMC article.
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.
Loriot Y, Kalebasty AR, Fléchon A, Jain RK, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar AV, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthélémy P, Bangs R, Tagawa ST. Loriot Y, et al. Among authors: beuzeboc p. Future Oncol. 2024;20(23):1621-1631. doi: 10.2217/fon-2023-1030. Epub 2024 Jun 5. Future Oncol. 2024. PMID: 38682560 Free PMC article.
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.
Loriot Y, Petrylak DP, Rezazadeh Kalebasty A, Fléchon A, Jain RK, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar AV, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthélémy P, Tagawa ST. Loriot Y, et al. Among authors: beuzeboc p. Ann Oncol. 2024 Apr;35(4):392-401. doi: 10.1016/j.annonc.2024.01.002. Epub 2024 Jan 18. Ann Oncol. 2024. PMID: 38244927 Free article. Clinical Trial.
261 results